| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,478,031 |
| 52
Week Range: |
$0.4435 - $0.4435 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
525,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$343,050 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-06-15 |
2025-03-14 |
2024-09-13 |
2023-09-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
See Remarks |
• • – |
2025-09-05 |
4 |
A |
$4.33 |
$16,359 |
D/D |
3,778 |
274,708 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-08-22 |
4 |
A |
$4.52 |
$16,358 |
D/D |
3,619 |
270,930 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-08-08 |
4 |
A |
$4.80 |
$16,354 |
D/D |
3,407 |
267,311 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-07-25 |
4 |
A |
$5.96 |
$16,360 |
D/D |
2,745 |
263,904 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-07-11 |
4 |
A |
$7.06 |
$16,358 |
D/D |
2,317 |
261,159 |
|
- |
|
| Harrison Thomas L |
|
– • – |
2025-07-01 |
4 |
A |
$3.46 |
$25,622 |
D/D |
7,401 |
16,299 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-06-27 |
4 |
A |
$4.76 |
$16,355 |
D/D |
3,436 |
258,842 |
|
- |
|
| Oday Steven J |
Chief Medical Officer |
• – – |
2025-06-18 |
4 |
A |
$4.47 |
$194,432 |
D/D |
43,497 |
57,116 |
|
- |
|
| Klaskin Christine M |
PFO & PAO |
• – – |
2025-06-18 |
4 |
A |
$4.47 |
$70,546 |
D/D |
15,782 |
23,478 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-06-18 |
4 |
A |
$4.47 |
$274,445 |
D/D |
61,397 |
255,406 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-06-13 |
4 |
A |
$4.70 |
$16,356 |
D/D |
3,480 |
194,009 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-05-30 |
4 |
A |
$3.43 |
$16,358 |
D/D |
4,769 |
190,529 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-05-16 |
4 |
A |
$3.48 |
$16,356 |
D/D |
4,700 |
185,750 |
|
- |
|
| Buell Jennifer |
|
– • – |
2025-05-02 |
4 |
A |
$3.11 |
$1,807 |
D/D |
581 |
19,738 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-05-02 |
4 |
A |
$3.11 |
$16,359 |
D/D |
5,260 |
181,060 |
|
- |
|
| Buell Jennifer |
|
– • – |
2025-04-18 |
4 |
A |
$2.08 |
$1,808 |
D/D |
869 |
19,157 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-04-18 |
4 |
A |
$2.08 |
$16,403 |
D/D |
7,886 |
175,800 |
|
- |
|
| Buell Jennifer |
|
– • – |
2025-04-04 |
4 |
A |
$1.56 |
$1,808 |
D/D |
1,159 |
18,288 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-04-04 |
4 |
A |
$1.56 |
$16,049 |
D/D |
10,288 |
167,914 |
|
- |
|
| Harrison Thomas L |
|
– • – |
2025-04-01 |
4 |
A |
$2.88 |
$25,626 |
D/D |
8,898 |
8,898 |
|
- |
|
| Buell Jennifer |
|
– • – |
2025-03-21 |
4 |
A |
$1.61 |
$1,808 |
D/D |
1,123 |
17,129 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-03-21 |
4 |
A |
$1.61 |
$14,881 |
D/D |
9,243 |
157,626 |
|
- |
|
| Buell Jennifer |
|
– • – |
2025-03-07 |
4 |
A |
$2.35 |
$961 |
D/D |
409 |
15,646 |
|
- |
|
| Armen Garo H |
See Remarks |
• • – |
2025-03-07 |
4 |
A |
$2.35 |
$14,880 |
D/D |
6,332 |
148,383 |
|
- |
|
| Buell Jennifer |
|
– • – |
2025-02-21 |
4 |
A |
$3.32 |
$1,809 |
D/D |
545 |
15,237 |
|
- |
|
226 Records found
|
|
Page 1 of 10 |
|
|
